Inflammation drug developer HCW Biologics' Q2 net loss widens

Hcw Biologics

14/08/2026 20:29

Overview
US biopharma firm's Q2 revenue rose yr/yr, driven by licensing agreement completion
Company posted higher Q2 net loss compared to prior year period
Company raised $5.6 mln in equity financings during the quarter

Outlook
Company says substantial doubt exists about ability to continue for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support

Result Drivers
LICENSING AGREEMENT - Q2 revenue increase was driven by completion of exclusive, worldwide licensing agreement with Beijing Trimmune Biotech and related post-transfer services
LOWER OPERATING EXPENSES - R&D and G&A expenses declined due to lower salaries, benefits, and clinical trial costs, partially offset by increased preclinical spending

Company press release: ID:nGNX5VJg5t

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Basic Share
 
$11.58
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for HCW Biologics Inc is $30.00, about 925.6% above its August 13 closing price of $2.93

Reuters Recommended Reads
Aug 13 - Rani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Aug 13 - MeiraGTx Q2 revenue jumps on Reogen license revenue
Aug 14 - VistaGen Q1 revenue rises on licensing agreement expiration

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)